<inglise> COUNCIL REGULATION (EC) No 2821/98 of 17 December 1998 amending, as regards withdrawal of the authorisation of certain antibiotics, Directive 70/524/EEC concerning additives in feedingstuffs </inglise>
<eesti> N&Otilde;UKOGU M&Auml;&Auml;RUS (E&Uuml;) nr 2821/98, millega muudetakse s&ouml;&ouml;dalisandeid k&auml;sitlevat direktiivi 70/524/EM&Uuml;, tunnistades teatavate antibiootikumide lubamise kehtetuks 17. detsember 1998 </eesti>
<inglise> THE COUNCIL OF THE EUROPEAN UNION, </inglise>
<eesti> EUROOPA LIIDU N&Otilde;UKOGU, </eesti>
<inglise> Having regard to the Treaty establishing the European Community, </inglise>
<eesti> v&otilde;ttes arvesse Euroopa &Uuml;henduse asutamislepingut, </eesti>
<inglise> Having regard to the 1994 Act of Accession, and in particular Article 151 in conjunction with Annex XV, Title VII(E) (4) thereof, </inglise>
<eesti> v&otilde;ttes arvesse 1994. aasta &uuml;hinemisakti, eriti selle artiklit 151 koos XV lisa VII osa E jao l&otilde;ikega 4, </eesti>
<inglise> Having regard to Council Directive 70/524/EEC of 23 November 1970 concerning additives in feedingstuffs (1), and in particular Article 11(3) thereof, </inglise>
<eesti> v&otilde;ttes arvesse s&ouml;&ouml;dalisandeid k&auml;sitlevat n&otilde;ukogu 23. novembri 1970. aasta direktiivi 70/524/EM&Uuml; (1), eesk&auml;tt selle artikli 11 l&otilde;iget 3, </eesti>
<inglise> Having regard to the proposal from the Commission, </inglise>
<eesti> v&otilde;ttes arvesse komisjoni ettepanekut </eesti>
<inglise> (1) Whereas the Kingdom of Sweden was authorised under Annex XV to the Act of Accession to maintain its legislation in force before accession until 31 December 1998 with regard to the prohibition of the use in feedingstuffs of additives belonging to the groups of antibiotics; whereas on 2 February 1998 Sweden submitted applications for adjustments accompanied by detailed scientific grounds for the antibiotics avilamycin, bacitracin zinc, flavophospholipol, ardacin and avoparcin, spiramycin, tylosin phosphate and virginiamycin; whereas the Commission is required to take a decision on the adjustment applications submitted by Sweden not later than 31 December 1998; </inglise>
<eesti> ning arvestades, et: 1) &uuml;hinemisakti XV lisa kohaselt lubati Rootsi Kuningriigil j&auml;tta kuni 31. detsembrini 1998 kehtima &uuml;hinemiseelsed siseriiklikud &otilde;igusaktid, mis keelavad antibiootikumide gruppi kuuluvad s&ouml;&ouml;dalisandid; Rootsi esitas 2. veebruaril 1998 taotluse ja &uuml;ksikasjaliku teadusliku p&otilde;hjenduse muudatuste tegemiseks antibiootikumide avilam&uuml;tsiini, tsinkbatsitratsiini, flavofosfolipooli, ardatsiini ja avopartsiini, spiram&uuml;tsiini, t&uuml;losiinfosfaati ning virginiam&uuml;tsiini kohta; komisjonil tuleb Rootsi esitatud muutmistaotluse kohta vastu v&otilde;tta otsus 31. detsembriks 1998; </eesti>
<inglise> (2) Whereas, under Article 11 of Directive 70/524/EEC, a Member State which, as a result of new information or of a reassessment of existing information made since the provisions in question were adopted, has detailed grounds for establishing that the use of one of the additives listed in the Directive constitutes a danger to animal or human health or the environment may temporarily suspend the authorisation to use that additive; </inglise>
<eesti> 2) kui liikmesriik p&auml;rast uute andmete saamist v&otilde;i olemasolevate andmete &uuml;mberhindamist, mis on toimunud p&auml;rast k&otilde;nesolevate s&auml;tete vastuv&otilde;tmist, teeb &uuml;ksikasjalikult p&otilde;hjendatud j&auml;relduse, et m&otilde;ne direktiivis 70/524/EM&Uuml; loetletud s&ouml;&ouml;dalisandi kasutamine kujutab endast ohtu loomade v&otilde;i inimeste tervisele v&otilde;i keskkonnale, v&otilde;ib ta mainitud direktiivi artikli 11 kohaselt selle s&ouml;&ouml;dalisandi lubamise ajutiselt peatada; </eesti>
<inglise> (3) Whereas the Republic of Finland, after expiry of the derogation granted to it under the Act of Accession, prohibited the use on its territory of tylosin phosphate and spiramycin in feedingstuffs from 1 January 1998 on the basis of the detailed grounds it had submitted on 12 March 1997 under the obligations laid down in the Act of Accession; </inglise>
<eesti> 3) p&auml;rast &uuml;hinemisaktis tema suhtes etten&auml;htud erandi t&auml;htaja l&otilde;ppemist keelas Soome Vabariik oma territooriumil t&uuml;losiinfosfaadi ja spiram&uuml;tsiini kasutamise loomas&ouml;&ouml;tades 1. jaanuarist 1998 &uuml;ksikasjalike p&otilde;hjenduste alusel, mis ta esitas 12. m&auml;rtsil 1997 &uuml;hinemisaktis etten&auml;htud kohustuse kohaselt; </eesti>
<inglise> (4) Whereas on 15 January 1998 the Kingdom of Denmark prohibited the use on its territory of virginiamycin in feedingstuffs; whereas it communicated the detailed grounds for that decision to the other Member States and the Commission on 13 March 1998 and 1 April 1998; </inglise>
<eesti> 4) Taani Kuningriik keelas 15. jaanuaril 1998 oma territooriumil virginiam&uuml;tsiini kasutamise loomas&ouml;&ouml;tades; ta esitas selle otsuse &uuml;ksikasjaliku p&otilde;hjenduse teistele liikmesriikidele ja komisjonile 13. m&auml;rtsil 1998 ja 1. aprillil 1998; </eesti>
<inglise> (5) Whereas, by virtue of Article 3a(e) of Directive 70/524/EEC, authorisation of an additive is not to be given if, for serious reasons concerning human or animal health, its use must be restricted to medical or veterinary purposes; </inglise>
<eesti> 5) kui inimeste v&otilde;i loomade tervist puudutavate kaalukate p&otilde;hjuste t&otilde;ttu tohib teatavat lisandit kasutada ainult meditsiini- v&otilde;i veterinaareesm&auml;rkidel, tuleb direktiivi 70/524/EM&Uuml; artikli 3a l&otilde;ike e kohaselt selle lubamisest s&ouml;&ouml;dalisandina keelduda; </eesti>
<inglise> (6) Whereas the authorisation of the glycopeptide avoparcin was withdrawn on 30 January 1997 (2) as an interim protective measure taken as a precaution; whereas that prohibition has to be reviewed by the Commission not later than 31 December 1998, on the basis of the results of the various investigations concerning the development of resistance by the use of antibiotics, in particular glycopeptides, and the programme of surveillance of antimicrobial resistance in animals which have received antibiotics, to be carried out in particular by the persons responsible for putting the additives concerned into circulation; whereas, since the Commission has received no new information to date, there is no reason for the prohibition to be reviewed; </inglise>
<eesti> 6) esialgse kaitse- ning ettevaatusabin&otilde;una tunnistati 30. jaanuaril 1997 (2) kehtetuks gl&uuml;kopeptiid avopartsiini lubamine; see keeld tuleb komisjonil uuesti l&auml;bi vaadata 31. detsembriks 1998, tuginedes antibiootikumide, eesk&auml;tt gl&uuml;kopeptiidide kasutamise t&otilde;ttu kujuneva resistentsuse uurimiste tulemustele, samuti antibiootikume saanud loomades mikroobivastaste ravimite suhtes kujuneva resistentsuse j&auml;relevalveprogrammi tulemustele, kusjuures selle j&auml;relevalveprogrammi t&auml;itjateks on eesk&auml;tt k&otilde;nesolevate s&ouml;&ouml;dalisandite ringlusse laskmise eest vastutajad; kuna komisjon ei ole mainitud andmeid veel saanud, ei ole k&auml;esoleval ajal vaja seda keeldu uuesti l&auml;bi vaadata; </eesti>
<inglise> (7) Whereas it was also decided as a precaution on 12 January 1998 (3) not to renew the authorisation of another glycopeptide, ardacin, until the results of research still to be carried out on avoparcin were available; </inglise>
<eesti> 7) 12 jaanuaril 1998 (3) otsustati samuti, et t&auml;iendava ettevaatusabin&otilde;una ei uuendata kuni avopartsiini uurimistulemuste saamiseni veel &uuml;he gl&uuml;kopeptiidi, ardatsiini, lubamist; </eesti>
<inglise> (8) Whereas the Commission consulted the Scientific Committee on Animal Nutrition (SCAN) on whether the use of tylosin phosphate and spiramycin should for serious reasons concerning animal or human health be restricted to veterinary medicine; whereas after examining the Finnish grounds for prohibiting the said macrolides as feed additives, the Committee stated in its opinion of 5 February 1998 that the data presented did not provide sufficient evidence that the use of macrolides as feed additives presented a significant risk to human or animal health and that, in the absence of sufficient research data on the epidemiology and spread of macrolide resistance, there was no reason for a ban on the use of the substances in question as additives; </inglise>
<eesti> 8) komisjon k&uuml;sis s&ouml;&ouml;tade teaduskomitee arvamust selle kohta, kas loomade v&otilde;i inimeste tervisega seotud teatavatel kaalukatel p&otilde;hjusel tuleb t&uuml;losiinfosfaadi ja spiram&uuml;tsiini kasutamist piirata &uuml;ksnes veterinaarmeditsiinilise otstarbega; uurinud l&auml;bi p&otilde;hjenduse, miks Soome mainitud makroliidide kasutamise loomas&ouml;&ouml;dalisanditena keelas, sedastas komisjon oma 5. veebruari 1998. aasta arvamuses, et esitatud andmed ei ole k&uuml;llaldased t&otilde;endamaks makroliidide s&ouml;&ouml;dalisandina kasutamisest tulenevat olulist ohtu inimeste v&otilde;i loomade tervisele ning et kuna pole k&uuml;llaldaselt uurimisandmeid makroliidiresistentsuse epidemioloogia ja leviku kohta, ei ole p&otilde;hjust keelata k&otilde;nesolevate ainete kasutamist s&ouml;&ouml;dalisanditena; </eesti>
<inglise> (9) Whereas SCAN acknowledges, however, that the wider use of macrolides as feed additives in the long run will contribute to the overall selective pressure for resistant bacteria to a significantly larger extent than would result from the use of macrolides for veterinary therapy alone; whereas SCAN acknowledges the probability that resistant enterococci or erm-resistance genes will be transferred from animals to humans will be higher, the higher the prevalence of resistant enterococci in animals is; whereas SCAN is of the opinion that the possibility that an increase in the resistance pool at animal level might pose risks to humans has been neither proven nor disproved, but that such a risk might be expected to be demonstrated; </inglise>
<eesti> 9) s&ouml;&ouml;tade teaduskomitee tunnistab siiski, et kaugemas perspektiivis suurendab makroliidide laialdane kasutamine s&ouml;&ouml;dalisandina &uuml;ldist selektiivset survet resistentsete bakterite kasuks m&auml;rkimisv&auml;&auml;rselt rohkem, kui seda teeks makroliidide kasutamine &uuml;ksnes loomade ravi otstarbel; s&ouml;&ouml;tade teaduskomitee tunnistab, et t&otilde;en&auml;osus resistentsete enterokokkide v&otilde;i erm-resistentsusgeenide &uuml;lekandumiseks loomadelt inimesele on seda suurem, mida suuremas &uuml;lekaalus on loomade organismis resistentseid enterokokke; s&ouml;&ouml;tade teaduskomitee on seisukohal, et arvamust, mille kohaselt resistentse populatsiooni kasvamine loomorganismide tasandil kujutab ohtu inimesele, ei ole veel kinnitatud ega ka &uuml;mber l&uuml;katud, kuid t&otilde;endite saamist selle ohu olemasolu kohta v&otilde;ib oodata edaspidi; </eesti>
<inglise> (10) Whereas SCAN also notes that tylosin-resistant enterococci isolated from pigs are almost all simultaneously resistant to erythromycin, an important macrolide antibiotic in human medicine notably in the treatment of respiratory infections; whereas it finds that, even if cross-resistance to lincosamides and streptogramins has not been tested in Finland, macrolide resistance in enterococci is, according to the literature, often or mostly encoded for by different erm-genes also conferring resistance to lincosamides and streptogramin B; whereas there is a clinical problem in human medicine if the enterococci resistant to macrolides include also a major resistance to streptogramin B; whereas two lincosamides are in clinical use in human medicine, namely lincomycin and clindamycin; whereas two streptogramins are clinically important in human medicine in the treatment of last resort of vancomycin resistant enterococci, namely pristinamycin and the combination dalfopristin/quinupristin; </inglise>
<eesti> 10) s&ouml;&ouml;tade teaduskomitee m&auml;rgib samuti, et peaaegu k&otilde;ik sigadelt eraldatud t&uuml;losiiniresistentsed enterokokid on samaaegselt resistentsed ka er&uuml;trom&uuml;tsiini suhtes (t&auml;htis makroliidide hulka kuuluv antibiootikum, mida kasutatakse inimmeditsiinis eesk&auml;tt respiratoorsete nakkushaiguste raviks); ta leiab, et kuigi Soomes ei ole katsetatud ristresistentsust linkosamiidide ja streptogramiinide suhtes, m&auml;&auml;ravad kirjanduse andmetel enterokokkide resistentsust makroliidide suhtes sageli v&otilde;i enamasti eri erm-geenid, mis samaaegselt m&auml;&auml;ravad ka resistentsust linkosamiidide ja streptogramiin B suhtes; kui makroliidide suhtes resistentsed enterokokid on suure resistentsusega ka streptogramiin B suhtes, tekitab see inimmeditsiinis kliinilisi probleeme; inimmeditsiinis kasutatakse ravi otstarbel kahte linkosamiidi, nimelt linkom&uuml;tsiini ja klindam&uuml;tsiini; vankom&uuml;tsiiniresistentsete enterokokkide vastase viimase abin&otilde;una on inimmeditsiinis kliiniliselt olulised kaks streptogramiini, nimelt pristinam&uuml;tsiin ja kombineeritud ravim dalfopristiin/kinupristiin; </eesti>
<inglise> (11) Whereas SCAN also notes that some experiments on mice have shown that in vivo transfer of erythromycin resistance from enterococci to other bacteria is possible; whereas it also specifies that erythromycin-resistant animal enterococci may colonise humans for a longer or shorter time period or may transfer their macrolide-resistance genes to the resident bacterial flora of humans, notably to human bacteria such as staphylococci or group A streptococci, which would constitute a clinical problem in human medicine, either directly after ingestion or via gene exchange in the environment, but that the frequencies of such transfers cannot be estimated; </inglise>
<eesti> 11) s&ouml;&ouml;tade teaduskomitee m&auml;rgib samuti, et m&otilde;ned katsed hiirtega on n&auml;idanud er&uuml;trom&uuml;tsiiniresistentsuse enterokokkidelt teistele bakteritele &uuml;lekandumise v&otilde;imalikkust in vivo; ta m&auml;rgib samuti, et loomades elavad er&uuml;trom&uuml;tsiiniresistentsed enterokokid v&otilde;ivad koloniseerida inimese organismi pikemat v&otilde;i l&uuml;hemat aega v&otilde;i oma makroliidiresistentsuse geene inimese bakterfloorale &uuml;le kanda, sealhulgas sellistele inimese organismis elavatele bakteritele nagu staf&uuml;lokokid v&otilde;i A-grupi streptokokid, mis v&otilde;ib tekitada inimmeditsiinis kliinilisi probleeme nii juhul, kui &uuml;lekanne toimub p&auml;rast allaneelamist v&otilde;i siis, kui geenid kanduvad &uuml;le keskkonna kaudu; sellise &uuml;lekandumise sagedust ei ole siiski v&otilde;imalik m&auml;&auml;rata; </eesti>
<inglise> (12) Whereas, in the light of the various abovementioned factors, the Commission, for its part, takes the view that there are sufficient grounds for a ban; whereas the risk of reducing the effectiveness of human medicinal products such as erythromycin in particular and possibly lincomycin, clindamycin, pristinamycin and the new combination dalfopristin/quinupristin, which is due to be authorised as a human medicinal product shortly, as a result of selection of cross-resistance caused by tylosin phosphate and spiramycin, should be avoided; </inglise>
<eesti> 12) pidades silmas mitmeid eespool mainitud tegureid, leiab komisjon, et keelamiseks on olemas k&uuml;llaldane alus; tuleb v&auml;ltida inimestel kasutatavate ravimite, eesk&auml;tt er&uuml;trom&uuml;tsiini ning t&otilde;en&auml;oliselt linkom&uuml;tsiini, klindam&uuml;tsiini, pristinam&uuml;tsiini ja peatselt inimestel kasutatava ravimina lubatava uue kombineeritud ravimi dalfopristiini/kinupristiini efektiivsuse v&auml;henemise ohtu, mis tuleneb t&uuml;losiinfosfaadi ja spiram&uuml;tsiini poolt p&otilde;hjustatud selektsioonist ristresistentsuse suunas; </eesti>
<inglise> (13) Whereas, moreover, spiramycin is used in human medicine and whereas therefore the resistances selected by the use of spiramycin as an additive increase the pool of spiramycin-resistance which could be transferred from animals to humans and thus make spiramycin less effective in human medicine; </inglise>
<eesti> 13) spiram&uuml;tsiini kasutatakse ka inimmeditsiinis ning sellet&otilde;ttu annab toimuv selektsioon resistentsuse suunas lisa spiram&uuml;tsiiniresistentsele populatsioonile, mis v&otilde;ib loomadelt inimesele &uuml;le kanduda ja p&otilde;hjustada spiram&uuml;tsiini efektiivsuse v&auml;henemist inimmeditsiinis; </eesti>
<inglise> (14) Whereas the Commission consulted SCAN on whether or not streptogramin-resistant E. faecium and staphylococci selected by the use of virginiamycin as a growth promoter constituted a public health risk at present or could constitute such a risk if streptogramins took a pivotal role for treatment of serious human infections in the future; </inglise>
<eesti> 14) komisjon k&uuml;sis s&ouml;&ouml;tade teaduskomitee arvamust selle kohta, kas streptogramiiniresistentsed E. faecium ja streptokokid, mis selekteeritakse virginiam&uuml;tsiini kasutamise t&otilde;ttu kasvustimulaatorina, kujutavad k&auml;esoleval ajal ohtu rahva tervisele v&otilde;i v&otilde;iksid sellist ohtu kujutada edaspidi, kui streptogramiinid omandaksid inimese raskete infektsioonide ravimisel t&auml;htsa koha; </eesti>
<inglise> (15) Whereas after examining the grounds put forward, the Committee concluded in its opinion of 10 July 1998 that the use of virginiamycin as a growth promoter did not constitute a real immediate risk to public health in Denmark since Denmark had provided no new evidence to substantiate the transfer of streptogramin resistance from organisms of animal origin to those resident in the human digestive tract, which would compromise the future use of human medicinal products; whereas it stresses that there is currently no need for streptogramins in Denmark as the existing therapeutic treatments for treating enterococci and staphylococci infections are still effective there; </inglise>
<eesti> 15) p&auml;rast esitatud p&otilde;hjenduste uurimist j&otilde;udis komisjon oma 10. juuli 1998. aasta otsuses j&auml;reldusele, et virginiam&uuml;tsiini kasutamine kasvustimulaatorina ei kujuta endast tegelikku vahetut ohtu rahva tervisele Taanis, kuna Taani ei ole esitanud uusi andmeid, mis t&otilde;endaksid streptogramiiniresistentsuse &uuml;lekandumist loomades elavatest organismidest inimese seedetraktis elavatele organismidele, mis v&otilde;iks edaspidi v&auml;hendada inimestel kasutatavate ravimite efektiivsust; ta r&otilde;hutab, et k&auml;esoleval ajal ei ole Taanis vajadust streptogramiine kasutusele v&otilde;tta, sest enterokokkide ja staf&uuml;lokokkide poolt p&otilde;hjustatud infektsioonide juba kasutusel olevad ravimeetodid on seal endiselt efektiivsed; </eesti>
<inglise> (16) Whereas, none the less, SCAN acknowledges that a reservoir of resistant genes within the animal population poses a potential risk for humans; whereas, contrary to the Commission, it is of the opinion that a full risk assessment cannot be made until, in particular, quantitative evidence of the extent of transfer of antimicrobial resistance from livestock sources is obtained; </inglise>
<eesti> 16) s&ouml;&ouml;tade teaduskomitee tunnistab siiski, et resistentsete geenide varud loomapopulatsioonides kujutavad potentsiaalset ohtu inimesele; ta on vastupidi komisjonile arvamusel, et ohtu ei ole v&otilde;imalik t&auml;ielikult hinnata seni, kuni ei ole saadud kvantitatiivseid andmeid, kui ulatuslik on eesk&auml;tt p&otilde;llumajandusloomadelt l&auml;htuva mikroobivastaste ravimite suhtes kujuneva resistentsuse &uuml;lekanne; </eesti>
<inglise> (17) Whereas SCAN is also concerned about the development of vancomycin resistance amongst enterococci and methicillin-resistant strains of Staphylococcus aureus, which are increasingly responsible for nosocomial infections, particularly in the United States and southern Europe; whereas that could make it necessary to use streptogramins as therapeutic agents of last resort to treat germs which have developed resistance to other antibiotics; </inglise>
<eesti> 17) s&ouml;&ouml;tade teaduskomitee tunneb samuti muret vankom&uuml;tsiiniresistentsuse v&auml;ljakujunemise p&auml;rast enterokokkidel ja metitsilliiniresistentsetel Staphylococcus aureus'e t&uuml;vedel, mis eriti Ameerika &Uuml;hendriikides ja L&otilde;una-Euroopas p&otilde;hjustavad &uuml;ha rohkem haiglanakkusi; seet&otilde;ttu v&otilde;ib tekkida vajadus kasutada raviainena streptogramiini kui viimast abin&otilde;u nende haigusetekitajate vastu, mis on omandanud resistentsuse muude antibiootikumide suhtes; </eesti>
<inglise> (18) Whereas, furthermore, SCAN notes in its opinion that the virginiamycin-resistant enterococci and staphylococci isolated from poultry and pigs all had cross-resistance to pristinamycin used in human medicine or the combination dalfopristin/quinupristin, which is due to be authorised as a human medicinal product shortly; </inglise>
<eesti> 18) peale selle m&auml;rgib s&ouml;&ouml;tade teaduskomitee oma arvamuses, et kodulindudelt ja sigadelt eraldatud virginiam&uuml;tsiiniresistentsed enterokokid ja staf&uuml;lokokid on k&otilde;ik ristresistentsed ka inimmeditsiinis kasutatava pristinam&uuml;tsiini v&otilde;i peatselt inimestel kasutatava ravimina lubatava uue kombineeritud ravimi dalfopristiini/kinupristiini suhtes; </eesti>
<inglise> (19) Whereas SCAN also indicates that transfer of the sat A gene conferring resistance to virginiamycin occurs in vitro between isogenic strains of Enterococcus faecium; whereas virginiamycin-resistant E. faecium were detected in 22 % of food originating from pigs and in 54 % of that originating from poultry; whereas there are genetic factors for virginiamycin resistance existing within the human population, although it is not known how widespread they are; whereas two strains of E. faecium resistant to virginiamycin and pristinamycin, one isolated from a Dutch farmer and the other from his poultry, have the same genetic fingerprint; whereas even if general conclusions about the transfer of resistant enterococci from animals to humans should not be drawn from a single case, the Commission sees it as an indication that this might be confirmed by other cases in the future; </inglise>
<eesti> 19) s&ouml;&ouml;tade teaduskomitee m&auml;rgib samuti, et isogeensete Enterococcus faecium'i t&uuml;vede vahel leiab aset virginiam&uuml;tsiiniresistentsuse geeni sat A &uuml;lekanne in vitro; virginiam&uuml;tsiiniresistentne E. faecium on avastatud 22% sea- ja 54% linnulihatoodetes; virginiam&uuml;tsiiniresistentsust m&auml;&auml;ravaid geneetilisi faktoreid esineb ka inimpopulatsioonis, kuid nende leviku ulatust ei teata; &uuml;helt hollandi talupidajalt ja tema kodulindudelt eraldatud kahel virginiam&uuml;tsiini- ja pristinam&uuml;tsiiniresistentsel E. faecium'i t&uuml;vel on &uuml;hesugune geneetiline s&otilde;rmej&auml;lg; kuigi &uuml;he juhtumi p&otilde;hjal ei ole v&otilde;imalik teha &uuml;ldist j&auml;reldust resistentsete enterokokkide loomadelt inimesele &uuml;lekandumise kohta, v&otilde;ivad komisjoni arvates uued juhtumid seda j&auml;reldust edaspidi kinnitada; </eesti>
<inglise> (20) Whereas, after the SCAN opinion, Denmark produced major fresh evidence in August 1998 demonstrating a transfer in vivo under experimental conditions in the gastro-intestinal tract of rats of the sat A gene, via a plasmid, between isogenic strains of E. faecium; </inglise>
<eesti> 20) s&ouml;&ouml;tade teaduskomitee arvamuse kohaselt on Taani augustis 1998 esitanud uued kaalukad andmed, mis t&otilde;endavad, et in vivo katsetes toimub rottide seedetraktis plasmiidide kaudu isogeensete E. faecium'i t&uuml;vede vahel geeni sat A &uuml;lekanne; </eesti>
<inglise> (21) Whereas, in the light of the foregoing, the Commission, for its part, takes the view that the risk of reducing the effectiveness of human medicinal products such as pristinamycin and the new combination dalfopristin/quinupristin, which is due to be authorised shortly as a human medicinal product, as a result of cross-resistance caused by virginiamycin should be avoided; </inglise>
<eesti> 21) eespool &ouml;eldut silmas pidades on komisjon omakorda seisukohal, et tuleb v&auml;ltida inimestel kasutatavate ravimite, nagu pristinam&uuml;tsiini ja peatselt inimestel kasutatava ravimina lubatava uue kombineeritud ravimi dalfopristiini/kinupristiini efektiivsuse v&auml;henemise ohtu, mis tuleneb virginiam&uuml;tsiinist p&otilde;hjustatud ristresistentsusest; </eesti>
<inglise> (22) Whereas bacitracin zinc, a cyclic polypeptide, is also used in human medicine mainly for topical treatment of infections of the skin and mucosal surfaces; whereas publications show that it could possibly be used for the treatment of vancomycin resistant enterococci, which represent a clinical problem in human medicine; whereas selected resistances from the use of bacitracin zinc as a feed additive inevitably increase the reservoir of resistances to bacitracin zinc; whereas the percentage of Enterococcus faecium resistant to bacitracin zinc is higher in chickens which have received bacitracin zinc than in chickens which have not received it; whereas these resistances could be transferred from animals to humans and reduce the effectiveness of bacitracin zinc used as a human medicinal product; whereas the effectiveness of bacitracin zinc in human medicine should therefore be preserved; </inglise>
<eesti> 22) tsinkbatsitratsiin (ts&uuml;kliline pol&uuml;peptiid) on kasutusel ka inimmeditsiinis peamiselt naha ja limaskesta pindmiste infektsioonide kohalikuks raviks; kirjanduse andmetel on v&otilde;imalik, et seda saab kasutada ka vahendina vankom&uuml;tsiiniresistentsete enterokokkide vastu, mis kujutavad endast kliinilist probleemi inimmeditsiinis; tsinkbatsitratsiini s&ouml;&ouml;dalisandina kasutamisest tingitud selektsioon resistensuse suunas suurendab v&auml;ltimatult tsinkbatsitratsiiniresistentsuse geenide varusid; tibudel, kes on saanud tsinkbatsitratsiini, on tsinkbatsitratsiiniresistentsete Enterococcus faecium'ide protsent suurem kui tibudel, kes ei ole seda saanud; see resistentsus v&otilde;ib &uuml;le kanduda loomadelt inimesele ja v&auml;hendada inimestel kasutatava ravimi tsinkbatsitratsiini efektiivsust; tsinkbatsitratsiini efektiivsus inimmeditsiinis tuleb s&auml;ilitada; </eesti>
<inglise> (23) Whereas according to the conclusions of the World Health Organisation conference held in Berlin in October 1997, the Economic and Social Committee of the European Union, the International Office of Epizootics and the conference on antibiotic resistance held in Copenhagen in September 1998, antibiotic resistance must henceforth be regarded as a major, complex problem of international dimensions; whereas, in the sense of the recommendations arising from these conferences, it is desirable to set up a system of general surveillance of antimicrobial resistance resulting from the use of antibiotics; whereas, furthermore, the phenomena of resistance encountered not only in hospitals but also in the general population should be addressed; </inglise>
<eesti> 23) 1997. aasta oktoobris Berliinis peetud Maailma Tervishoiuorganisatsiooni konverentsi, Euroopa Liidu majandus- ja sotsiaalkomitee, rahvusvahelise episootiaameti ja 1998. aasta septembris Kopenhagenis peetud antibiootikumiresistentsusalase konverentsi j&auml;relduste kohaselt tuleb resistentsust antibiootikumide suhtes k&auml;sitleda t&auml;htsa rahvusvahelise ulatusega liitprobleemina; nende konverentside n&otilde;uannete kohaselt on soovitav luua antibiootikumide kasutamisest tuleneva mikroobivastaste ainete suhtes avalduva resistentsuse &uuml;ldise j&auml;relevalve s&uuml;steem; lisaks sellele tuleb p&uuml;&uuml;da piir panna nii haiglates kui ka kogu elanikkonna hulgas avalduvatele resistentsuseilmingutele; </eesti>
<inglise> (24) Whereas medicinal products belonging to new classes of antibiotics are not ready to be approved in the immediate future; whereas it is therefore imperative to preserve the effectiveness of those human medicinal products which are still effective; </inglise>
<eesti> 24) uutesse antibiootikumiklassidesse kuuluvaid ravimeid ei saa veel l&auml;hitulevikus heaks kiita; seega on h&auml;davajalik s&auml;ilitada seni veel toimivate inimestel kasutatavate ravimite efektiivsus; </eesti>
<inglise> (25) Whereas one of the ways of achieving that aim, along with others relating to use of human medicinal products, is not to increase the reservoir of resistances in animals, especially where such resistances could be transferred to humans, thereby reducing the effectiveness of human medicinal products; whereas numerous scientific data demonstrate such a transfer not only for the organisms responsible for zoonoses but also for commensals; </inglise>
<eesti> 25) &uuml;ks tee selle eesm&auml;rgi saavutamisel koos inimeste kasutatavatesse ravimitesse puutuvate muude abin&otilde;udega on mitte suurendada resistentsusegeenide varu loomades, eriti juhul, kui see resistentsus v&otilde;ib &uuml;le kanduda inimesele ja v&auml;hendada inimestel kasutatavate ravimite efektiivsust; rohkearvulised teadusuuringute andmed n&auml;itavad, et see &uuml;lekandumine ei toimu mitte ainult zoonoose tekitavate mikroorganismide, vaid ka kommensaalide puhul; </eesti>
<inglise> (26) Whereas one of the ways of preventing such a phenomenon, which originates in the use in livestock farming of antibiotics administered either as a veterinary medicinal product or as a feed additive, is no longer to authorise the use of antibiotics authorised as human medicinal products or known to select cross-resistance to antibiotics used in human medicine as additives, restricting the use of such substances for fundamental reasons to human medicine; </inglise>
<eesti> 26) kui k&otilde;nesolev n&auml;htus on p&otilde;hjustatud loomaravimitena v&otilde;i s&ouml;&ouml;dalisanditena manustatavate antibiootikumide kasutamisest loomakasvatuses, on selle v&auml;ltimise &uuml;ks teid edaspidi mitte lubada s&ouml;&ouml;dalisanditena kasutada antibiootikume, mis on inimestel kasutatavate ravimitena heaks kiidetud v&otilde;i mille kohta on teada, et need p&otilde;hjustavad ristresistentsust inimestel kasutatavate ravimitena antibiootikumide suhtes, ja oluliste eesm&auml;rkide t&otilde;ttu piirduda mainitud ainete kasutamisel inimmeditsiiniga; </eesti>
<inglise> (27) Whereas, for the sake of protecting human health, the authorisations for the antibiotics bacitracin zinc, spiramycin, virginiamycin and tylosin phosphate should be withdrawn; </inglise>
<eesti> 27) antibiootikumide tsinkbatsitratsiini, spiram&uuml;tsiini, virginiam&uuml;tsiini ja t&uuml;losiinfosfaadi lubamine tuleb inimese tervise kaitse eesm&auml;rgil tunnistada kehtetuks; </eesti>
<inglise> (28) Whereas, on the basis of current scientific and technical knowledge, it would appear, however, that the evidence presented by the Kingdom of Sweden does not justify withdrawal of the authorisations for the antibiotics monensin sodium and salinomycin sodium, of the ionophore group, since no ionophore is to date used in veterinary or human medicine and the two substances, in the current state of knowledge, do not select cross-resistance to antibiotics used in human or veterinary medicine; </inglise>
<eesti> 28) olemasolevatest teadus- ja tehnikauuringute andmetest ilmneb siiski, et Rootsi Kuningriigi poolt esitatud t&otilde;endid ei &otilde;igusta ionofooride grupi antibiootikumide monensiinnaatriumi ja salinom&uuml;tsiinnaatriumi lubamise kehtetuks tunnistamist, kuna k&auml;esolevaks ajaks ei ole veterinaar- ega inimmeditsiinis veel kasutusele v&otilde;etud &uuml;htegi ionofoori ning olemasolevatel andmetel ei p&otilde;hjusta kaks mainitud ainet selektsiooni inim- v&otilde;i veterinaarmeditsiinis kasutatavate antibiootikumide suhtes avalduva ristresistentsuse suunas; </eesti>
<inglise> (29) Whereas the prohibition on the use of the antibiotics bacitracin zinc, spiramycin, virginiamycin and tylosin phosphate ought to be perceived as an interim protective measure taken as a precaution, which could be reconsidered in the light of the investigations which will have been carried out and of the established surveillance programme; </inglise>
<eesti> 29) antibiootikumide tsinkbatsitratsiini, spiram&uuml;tsiini, virginiam&uuml;tsiini ja t&uuml;losiinfosfaadi keelamist tuleb k&auml;sitleda esialgse kaitse- ning ettevaatusabin&otilde;una, mille v&otilde;ib uuesti l&auml;bi vaadata, silmas pidades edasiste uuringute ning j&auml;relevalveprogrammide tulemusi; </eesti>
<inglise> (30) Whereas, on the basis of current scientific and technical knowledge, it would also appear that the evidence presented by the Kingdom of Sweden does not justify a ban on the antibiotic flavophospholipol of the phosphoglycopeptide group since no substance belonging to the same group is to date used in veterinary or human medicine and flavophospholipol, in the current state of knowledge, does not select cross-resistance to antibiotics used in human or veterinary medicine; </inglise>
<eesti> 30) olemasolevatest teadus- ja tehnikauuringute andmetest ilmneb samuti, et Rootsi Kuningriigi poolt esitatud t&otilde;endid ei &otilde;igusta fosfogl&uuml;kopeptiidide grupi antibiootikumi flavofosfolipooli keelamist, kuna k&auml;esolevaks ajaks ei ole veterinaar- ega inimmeditsiinis veel kasutusele v&otilde;etud &uuml;htegi samasse gruppi kuuluvat ainet ning olemasolevatel andmetel ei p&otilde;hjusta flavofosfolipool selektsiooni inim- ega veterinaarmeditsiinis kasutatavate antibiootikumide suhtes avalduva ristresistentsuse suunas; </eesti>
<inglise> (31) Whereas, on the basis of current scientific and technical knowledge it would appear that the evidence presented by the Kingdom of Sweden does not justify a ban on the antibiotic avilamycin, belonging to the group of orthosomycins, since no substance belonging to that group is to date used in human medicine; whereas that decision will be reviewed in the light of additional studies to be supplied by the person responsible for the entry into circulation of avilamycin, concerning the mechanisms of resistance, the development of resistance in certain micro-organisms and in particular Enterococcus faecium, and any cross-resistance to everninomycin, which is currently under development with a view to future approval for use in human medicine or to other substances used in human medicine having the same site of action as avilamycin; </inglise>
<eesti> 31) olemasolevatest teadus- ja tehnikauuringute andmetest ilmneb, et Rootsi Kuningriigi poolt esitatud t&otilde;endid ei &otilde;igusta ortosom&uuml;tsiinide grupi antibiootikumi avilam&uuml;tsiini keelamist, kuna k&auml;esolevaks ajaks ei ole inimmeditsiinis veel kasutusele v&otilde;etud &uuml;htegi samasse gruppi kuuluvat ainet; selle otsuse v&otilde;ib uuesti l&auml;bi vaadata, silmas pidades avilam&uuml;tsiini ringlusse laskmise eest vastutaja poolt esitatud t&auml;iendavate uuringute andmeid resistentsuse mehhanismi kohta, resistentsuse kujunemise kohta teatavatel mikroorganismidel, eesk&auml;tt Enterococcus faecium'il ning v&otilde;imaliku ristresistentsuse kohta, mis avaldub k&auml;esoleval ajal veel v&auml;ljat&ouml;&ouml;tamisel oleva ja ehk edaspidi inimmeditsiinis kasutusele tuleva everninom&uuml;tsiini v&otilde;i muude inimmeditsiinis kasutatavate ainete suhtes, millel on avilom&uuml;tsiiniga &uuml;hine toimeetapp; </eesti>
<inglise> (32) Whereas the maintenance of the authorisations for monensin sodium, salinomycin sodium, flavophospholipol and avilamycin will have to be reviewed in the light of the results of the work on antimicrobial resistance carried out by the working group set up by the Scientific Steering Committee; </inglise>
<eesti> 32) monensiinnaatriumi, salinom&uuml;tsiinnaatriumi, flavofosfolipooli ja avilam&uuml;tsiini lubamine tuleb uuesti l&auml;bi vaadata, silmas pidades tulemusi, mis saadakse mikroobivastaste ravimite suhtes avalduva resistentsuse uurimisel, mida teeb juhtiva teaduskomitee moodustatud t&ouml;&ouml;r&uuml;hm; </eesti>
<inglise> (33) Whereas after 31 December 1998 the Kingdom of Sweden is required to apply the Community legislation on feed additives in its entirety; </inglise>
<eesti> 33) p&auml;rast 31. detsembrit 1998 tuleb Rootsi Kuningriigil rakendada &uuml;henduse s&ouml;&ouml;dalisandeid k&auml;sitlevaid &otilde;igusakte t&auml;ies mahus; </eesti>
<inglise> (34) Whereas a transitional period to comply with the provisions of this Regulation is necessary in the Member States where one or more of the additives referred to in Article 1 are authorised at present; </inglise>
<eesti> 34) liikmesriikides, kus k&auml;esoleval ajal on lubatud &uuml;ks v&otilde;i mitu artiklis 1 m&auml;rgitud s&ouml;&ouml;dalisandit, on vaja k&auml;esoleva m&auml;&auml;ruse s&auml;tetele vastavuse saavutamiseks rakendada &uuml;leminekuaega; </eesti>
<inglise> (35) Whereas, in the absence of an opinion of the Standing Committee on Feedingstuffs, the Commission has been unable to adopt the provisions it envisaged under the procedures laid down in Articles 23 and 24 of Directive 70/524/EEC, </inglise>
<eesti> 35) kuna alalise s&ouml;&ouml;dakomitee arvamus puudub, ei ole komisjon saanud vastu v&otilde;tta s&auml;tteid, mis ta kavandas direktiivi 70/524/EM&Uuml; artiklites 23 ja 24 etten&auml;htud korras, </eesti>
<inglise> HAS ADOPTED THIS REGULATION: </inglise>
<eesti> ON VASTU V&Otilde;TNUD K&Auml;ESOLEVA M&Auml;&Auml;RUSE. </eesti>
<inglise> Article 1 </inglise>
<eesti> Artikkel 1 </eesti>
<inglise> The entries in Annex B to Directive 70/524/EEC for the following antibiotics shall be deleted: </inglise>
<eesti> K&auml;esolevaga kustutatakse direktiivi 70/524/EM&Uuml; B lisa kirjed j&auml;rgmiste antibiootikumide kohta: </eesti>
<inglise> - bacitracin zinc, </inglise>
<eesti> - tsinkbatsitratsiin, </eesti>
<inglise> - spiramycin, </inglise>
<eesti> - spiram&uuml;tsiin, </eesti>
<inglise> - virginiamycin, </inglise>
<eesti> - virginiam&uuml;tsiin, </eesti>
<inglise> - tylosin phosphate. </inglise>
<eesti> - t&uuml;losiinfosfaat. </eesti>
<inglise> Article 2 </inglise>
<eesti> Artikkel 2 </eesti>
<inglise> The Commission shall reexamine the provisions of this Regulation before 31 December 2000 on the basis of the results given by </inglise>
<eesti> Komisjon vaatab k&auml;esoleva m&auml;&auml;ruse s&auml;tted uuesti l&auml;bi 31. detsembriks 2000, v&otilde;ttes aluseks tulemused, mis on saadud: </eesti>
<inglise> - the different investigations concerning the induction of resistances by the use of the antibiotics concerned, </inglise>
<eesti> - mitmesugustes uurimist&ouml;&ouml;des resistentsuse kohta, mis on tekkinud vastavate antibiootikumide kasutamise t&otilde;ttu, </eesti>
<inglise> and </inglise>
<eesti> ning </eesti>
<inglise> - the surveillance programme of microbial resistance in animals which have received antibiotics, to be carried out in particular by the persons responsible for putting the additives concerned into circulation. </inglise>
<eesti> - antibiootikume saavates loomades elavate mikroobide resistentsuse j&auml;relevalveprogrammi tulemusena, kusjuures selle j&auml;relevalveprogrammi t&auml;itjateks on eesk&auml;tt asjassepuutuvate s&ouml;&ouml;dalisandite ringlusse laskmise eest vastutajad. </eesti>
<inglise> Article 3 </inglise>
<eesti> Artikkel 3 </eesti>
<inglise> This Regulation shall enter into force on the day of its publication in the Official Journal of the European Communities. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus j&otilde;ustub Euroopa &Uuml;henduste Teatajas avaldamise p&auml;eval. </eesti>
<inglise> It shall apply from 1 January 1999. </inglise>
<eesti> K&auml;esolevat m&auml;&auml;rust kohaldatakse alates 1. jaanuarist 1999. </eesti>
<inglise> However, where, on the date on which this Regulation enters into force, a Member State has not banned, in accordance with Community law, one or more of the antibiotics referred to in Article 1 of this Regulation, such antibiotic or antibiotics shall remain authorised in that Member State until 30 June 1999. </inglise>
<eesti> Kui k&auml;esoleva m&auml;&auml;ruse j&otilde;ustumise kuup&auml;evaks m&otilde;ni liikmesriik ei ole siiski koosk&otilde;las &uuml;henduse &otilde;igusega keelanud &uuml;hte v&otilde;i enamat k&auml;esoleva m&auml;&auml;ruse artiklis 1 m&auml;rgitud antibiootikumi, on see (need) antibiootikum(id) selles liikmesriigis lubatud kuni 30. juunini 1999. </eesti>
<inglise> This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 17 December 1998. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus on tervikuna siduv ja vahetult kohaldatav k&otilde;ikides liikmesriikides. </eesti>
<inglise> For the Council The President </inglise>
<eesti> Br&uuml;ssel, 17. detsember 1998 </eesti>
<inglise> W. MOLTERER (1) OJ L 270, 14.12.1970, p. 1. Directive as last amended by Commission Directive 98/19/EC (OJ L 96, 28.3.1998, p. 39). </inglise>
<eesti> N&otilde;ukogu nimel eesistuja W. MOLTERER </eesti>
<inglise> (2) Commission Directive 97/6/EC of 30 January 1997 amending Council Directive 70/524/EEC concerning additives in feedingstuffs (OJ L 35, 5.2.1997, p. 11). (3) Commission Directive 97/72/EC of 15 December 1997 amending Council Directive 70/524/EEC concerning additives in feedingstuffs (OJ L 351, 23.12.1997, p. 55). </inglise>
<eesti> (1) E&Uuml;T L 270, 14.12.1970, lk 1. Direktiivi on viimati muudetud komisjoni direktiiviga 98/19/E&Uuml; (E&Uuml;T L 96, 28.03.1998, lk 39). (2) Komisjoni 30. jaanuari 1997. aasta direktiiv 97/6/E&Uuml;, millega muudetakse n&otilde;ukogu s&ouml;&ouml;dalisandeid k&auml;sitlevat direktiivi 70/524/EM&Uuml; (E&Uuml;T L 35, 5.02.1997, lk 11). (3) Komisjoni 15. detsembri 1997. aasta direktiiv 97/72/E&Uuml;, millega muudetakse n&otilde;ukogu s&ouml;&ouml;dalisandeid k&auml;sitlevat direktiivi 70/524/EM&Uuml; (E&Uuml;T L 351, 23.12.1997, lk 55). </eesti>
 